Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesGemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
Cancer, 06/01/09
Cassier PA et al. – Gemcitabine-oxaliplatin combination (GEMOX) is active and well tolerated in pretreated pts with metastatic neuroendocrine tumors.
Methods- Study of GEMOX efficacy in treatment of pts with metastatic neuroendocrine tumors
- GEMOX treatment for 20 consecutive pts with progressive disease, most cases after failure of other chemotherapy regimens (median 2 regimens)
- Follow-up for evidence of toxicity, response, and survival
- Exclusion from efficacy analysis of 2 pts chemotherapy-naive at treatment initiation
- Toxicity manageable overall
- Treatment discontinuation due to oxaliplatin-induced neurotoxicity (grade 2) in 6 pts (30%)
- Partial response for 3 (17%) of 18 pts
- Median progression-free survival: 7 mo
- Median overall survival: 23.4 mo
Related Articles
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Relevance Score: 95%
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Journal of Clinical Oncology, 11/13/09
Relevance Score: 93%
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09
Relevance Score: 91%
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 91%
Today in Neuroendocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Free testosterone levels in umbilical-cord blood predict infant head circumference in females
Developmental Medicine & Child Neurology, 12/08/09
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy
Metabolism-Clinical and Experimental, 12/08/09
Role of the Perifornical Hypothalamic Monoamine Neurotransmitter Systems in Anorectic Effects of Endotoxin
Neuroendocrinology, 12/01/09
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression
BMC Cancer, 12/08/09
DO Intracranial Neoplasms Differ in Ollier Disease and Maffucci Syndrome? An in-Depth Analysis of the Literature
Neurosurgery, 12/07/09
Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy
Journal of Neuro-Oncology, 12/07/09
Sponsor
Article Search
Sponsor